D.A. Davidson & Co’s NovoCure NVCR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-5,940
Closed -$247K 1371
2023
Q2
$247K Sell
5,940
-2,063
-26% -$128K ﹤0.01% 1171
2023
Q1
$481K Sell
8,003
-2,004
-20% -$160K 0.01% 906
2022
Q4
$734K Sell
10,007
-72
-0.7% -$5.42K 0.01% 726
2022
Q3
$766K Buy
10,079
+941
+10% +$73.4K 0.01% 678
2022
Q2
$635K Sell
9,138
-228
-2% -$17.2K 0.01% 745
2022
Q1
$776K Buy
9,366
+3,440
+58% +$253K 0.01% 726
2021
Q4
$445K Sell
5,926
-1,635
-22% -$164K ﹤0.01% 915
2021
Q3
$878K Buy
7,561
+2,501
+49% +$378K 0.01% 669
2021
Q2
$1.12M Buy
5,060
+1,436
+40% +$279K 0.01% 595
2021
Q1
$479K Sell
3,624
-1,607
-31% -$254K 0.01% 820
2020
Q4
$905K Buy
+5,231
New +$716K 0.01% 527
2019
Q2
Sell
-8,342
Closed -$402K 1106
2019
Q1
$402K Buy
8,342
+1,260
+18% +$60.6K 0.01% 750
2018
Q4
$237K Buy
7,082
+478
+7% +$17.5K ﹤0.01% 906
2018
Q3
$346K Sell
6,604
-90
-1% -$3.58K 0.01% 852
2018
Q2
$210K Buy
+6,694
New +$186K ﹤0.01% 1025

Other funds holding NVCR

D.A. Davidson & Co's NVCR Position: Q3 2023 in Review

D.A. Davidson & Co sold out of NovoCure (NVCR) in Q3 2023, closing a stake of 5,940 shares — an estimated $247K sold.

D.A. Davidson & Co first reported a position in NVCR in Q2 2018 and held it in 15 quarters. The position peaked at $1.12M in Q2 2021. 226 funds tracked by Wall St. Rank hold NVCR as of Q3 2023.

  • D.A. Davidson & Co reported no remaining NovoCure position as of Q3 2023 after selling out during the quarter.
  • D.A. Davidson & Co sold 5,940 NovoCure shares in Q3 2023, an estimated $247K.
  • D.A. Davidson & Co first reported a position in NovoCure in Q2 2018 and held it in 15 quarters.
  • D.A. Davidson & Co's NovoCure position peaked at $1.12M in Q2 2021.
  • 226 funds tracked by Wall St. Rank held NovoCure as of Q3 2023.

Based on D.A. Davidson & Co's 13F filing for Q3 2023, filed 8 Nov 2023.